跳至主要内容
临床试验/ISRCTN47722295
ISRCTN47722295进行中(未招募)4 期

An open-label study evaluating the efficacy and safety of budesonide in the treatment of patients with immunoglobulin A nephropathy

Institutul Clinic Fundeni0 个研究点目标入组 32 人开始时间: 2020年2月14日最近更新:

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
32

研究概览

简要总结

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37978255/ (added 20/11/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged =18 years
  • 2. Patients with a histological diagnosis of IgA nephropathy
  • 3. Patients with primary IgA nephropathy
  • 4. Patients with persistent proteinuria over 1g/day despite adequate renin-angiotensin-aldosterone system (RAAS) blockade or patients with proteinuria between 0.5 and 1 g/day after RAAS blockade if they had additional risk factors for progression (estimated glomerular filtration rate below 60 ml/min/1.73m², presence of proliferative lesions on kidney biopsy)

排除标准

  • 1. IgAN associated with other disorders (viral infections, autoimmune disorders, malignancy)
  • 2. Estimated glomerular filtration rate below 20 ml/min/1.73m²
  • 4. Nephrotic syndrome or a rapidly progressive clinical course
  • 5. Proteinuria below 0.5 g/day after adequate RAAS blockade.
  • 6. Severe histological lesions of activity or chronicity (endocapillary hypercellularity in over 50% of examined glomeruli, crescents in over 30% of examined glomeruli, presence of fibrinoid necrosis, global glomerulosclerosis in over 50% of examined glomeruli)
  • 7. Diabetes mellitus or active infections
  • 8. Received prior immunosuppression

研究者

相似试验

Stabilization of kidney function in patients... | 临床试验